Monogenic and Syndromic
Obesity
Sonali Malhotra, MD
Pediatric Endocrinology/Obesity Medicine
Diplomate, ABOM
Harvard Medical School
Massachusetts General Hospital for Children
Disclosures
Speaker Bureau: Rhythm Pharmaceuticals
Learning Objectives
Review the energy balance regulation pathway.
To introduce rare disorders of obesity, also known as monogenic
obesity.
Review clinical features of syndromic genetic disorders that cause
obesity
Objectives
To discuss the energy balance regulation
To introduce rare disorders of obesity, also known as monogenic
obesity.
Review clinical features of syndromic genetic disorders that cause
obesity
Gut-to-brain hunger signaling
AdipocytesGI tract Stomach Pancreas
I’m full
(anorexigenic)
Food intake
Energy Expenditure
NPY/AGRP
neurons
Ada
p
ted from Nature Reviews Genetics. 2005.
POMC/CART
neurons
LEPR
Y2R
GHSR
PYY
Leptin
Ghrelin
Insulin
Second order
neurons in PVN
hypothalamus
MC4R
Y1R
I’m hungry
(orexigenic)
Food intake
Energy Expenditure
LEPR
ɲ-MSH
POMC
BBS1-20
ALMS1
Courtesy Dr. Laurie
Braun
Objectives
To discuss the energy balance regulation
To introduce rare disorders of obesity, also known as monogenic
obesity.
Review clinical features of syndromic genetic disorders that cause
obesity
Congenital Leptin
Deficiency
Cause: mutations in gene for leptin (LEP)
Phenotype: Hyperphagia with severe, early
onset obesity, altered immune function and
delayed puberty
Prevalence: EXTREMELY RARE – only
several case reports in consanguineous
families*
Diagnostic test: leptin level (undetectable),
genetic testing
Treatment: recombinant leptin
*Mostly found in consanguineous families.
Adapted from Bell CG, et al. Nat Rev Genet. 2005;6(3):221-34.
Monogenic Obesity
Leptin deficiency
Case
Female patient with rapid early onset
weight gain at 4 months of age
Hyperphagia ( demanding food
continuously, ate much more than siblings)
Developed growth abnormalities in leg
bones
-corrective leg surgery
-liposuction of lower limb fat to try to
improve mobility
Montague et al Nature. 1997;387:903–908
Leptin deficiency
Case continued..
Endocrine tests
- Serum Leptin undetectable
- Insulin ( Elevated markedly)
- Proinsulin ( 4 times the ULN)
Genetic tests:
- Homozygous LEP frameshift mutation detected
- Parents were heterozygous
Eligible for treatment with recombinant human leptin replacement
Montague et al Nature. 1997;387:903–908
Leptin
treatment in
Leptin
deficiency
Source: Endocrinology Reviews
Leptin receptor
deficiency
Cause: mutations in gene for leptin
receptor (LEPR)
Phenotype: Hyperphagia with severe,
early-onset obesity and problems with
sexual development [same as leptin
deficiency]
Prevalence: EXTREMELY RARE- only
several case reports*
Diagnostic test: leptin level [very high],
genetic testing
Treatment: none available, MC4R agonist
in development
Monogenic Obesity:
Leptin Receptor Deficiency:
Whats Next?
Adapted from Bell CG, et al. Nat Rev Genet. 2005;6(3):221-34.
Impaired activation of
POMC neurons
Leading to lack of
MSH signaling
? Therefore, MC4R
agonist might be of
therapeutic benefit.
LEPR Deficiency
Case 2
2-year-old female presents with
progressive severe obesity from
birth
Consoled only by food
Parents were unable to maintain
nutritional plan owing to
hyperphagia
Kleinendorst L, et al. BMJ Case Rep. 2017;2017:bcr-2017-
221067.
Image reproduced from Kleinendorst L, et al. BMJ Case Rep.
2017;2017:bcr-2017-221067.
ih i i f blihi d
Case report: Leptin receptor
deficiency
No developmental delays or other abnormal clinical features
present.
Thyroid and cortisol levels normal
Leptin levels elevated because of fat mass
Sequenced MC4R and found no mutations
-Subsequently sequenced 52 obesity related genes.
Found compound heterozygous LEPR mutations
POMC mutations
(Pro-opiomelanocortin)
M
Monogenic Obesity:
Cause: mutation in POMC gene
Phenotype: early-onset obesity, adrenal
insufficiency, red hair
Prevalence: <1/1,000,000
Diagnostic test: distinct phenotype, low cortisol,
genetic testing
Treatment:
o Hydrocortisone replacement for adrenal
insufficiency
Krude, Gruters, Trends in
Endocrinology & Metabolism, 2000.
adrenal
adrenal
insufficiency
red hair
POMC Deficiency:
Case Report
2-year-old Hispanic boy presents with
early onset severe obesity
-Neonatal Hypoglycemia
-Frequent respiratory infections
-Speech and motor delay
Marked Hyperphagia
Associated Adrenal Insufficiency and
hypothyroidism
-Hydrocortisone and levothyroxine
replacement
Hilado and Randhawa.J Pediatric Endocrinol Metab.2018;31:815-819
POMC Deficiency:
Case 3 (contd)
Negative testing for Prader-
Willi syndrome
Identified homozygous
POMC mutation in exon 3
Patient was treated with
metformin
Over a 3-year metformin
treatment span, BMI
decreased from 34.9
kg/m
2
to 32.9 kg/m
2
BMI = body mass index.
Millington GW. Nutr Metab (Lond). 2007;4:18. Open Access.
POMC Deficiency: What next? MC4R agonists
PC1/3 mutations
(Pro-hormone convertase)
M
Monogenic Obesity:
Cause: mutation in PCSK1 gene
Phenotype: severe obesity, low insulin, chronic
diarrhea, problems with sexual development
Prevalence: VERY rare- only several case reports*
Diagnostic test: high pro-hormone levels, genetic
testing
Treatment:
o Hormone replacement
PC1/3
PCSK1 Deficiency
Case Report
6-year-old male with severe
early onset obesity
Malabsorptive diarrhea noted
at the age of 8 days
During first year of life required
specialized formulas for weight
gain
Reported to be hyperphagic
with food seeking behavior at
the age of 2 .
Farooqi et al.JCEM 2007;92:3369-3373
PCSK1 Deficiency
Case 4 (contd)
Proinsulin levels markedly elevated (1079 pmol/L Ref
range: <7 pmol/l), with insulin abnormally low.
Low serum cortisol (as defects in cleaving POMC):
Treated with hydrocortisone
Elevated ACTH precursor
(549 pmol/l Ref range:78 pmol/l)
Low free T
4
T
4
= thyroxine.
Farooqi IS, et al. J Clin Endocrinol Metab. 2007;92(9):3369-73.
Clinical features of severe early onset obesity,
abnormal Insulin/proinsulin ratio and
sequencing diagnosed with prohormone
convertase (PC) 1/3 deficiency
MC4R mutationsM
Monogenic Obesity:
Cause: mutations in MC4R receptor
(autosomal dominant)
Phenotype: Normal mental status;
Increased fat and lean mass with increased
bone mineral density
Accelerated linear growth( tall stature)
Hyperinsulinemia
Prevalence: General population at 1:2000
Prevalence in patients with obesity :0.5 to 1%
Diagnosis : genetic testing
Treatment: MC4R Agonist (Rhythm) in
development
Learning Objectives
Review the energy balance regulation pathway.
To introduce rare disorders of obesity, also known as monogenic
obesity.
Review clinical features of syndromic genetic disorders that cause
obesity
S
Syndromic obesity
The most frequent forms of syndromic obesity are Prader-Willi
and Bardet-Biedl syndrome.
Not a single gene mutation but multiple genes are effected-- and have
more features besides just obesity
Mechanism of obesity is less well understood
Prader-Willi Syndrome
Prader-Willi Syndrome
Prader-Willi Syndrome
Prader-Willi Syndrome
Clinical characteristics of
Prader-Willi Syndrome
Birth to 2 years :
Hypotonia with poor suck
2–6 years
Hypotonia with poor suck
Global developmental delays
6–12 years :
History of hypotonia with poor suck
Global developmental delay
Excessive eating
(hyperphagia, obsession with food)
Central obesity
Cassidy, S., & Driscoll, D. (2009). EJHG, 17(1), 3-13.
Clinical characteristics of
Prader-Willi Syndrome
12 years through adulthood
Intellectual disability
Hyperphagia with central obesity
Hypothalamic hypogonadism
Typical behavior problems
(including temper tantrums and
compulsive features)
Cassidy, S., & Driscoll, D. (2009). EJHG, 17(1), 3-13.
Bardet-Biedl Syndrome (BBS)
Mutation in BBS genes
BBS genes are involved in
trafficking LEPR to the
neuronal cell surface
Also genetic defect in cilia
Clinical Characteristics
Diagnostic criteria : 4 primary features
OR 3 primary plus 2 secondary features
Primary Criteria:
-Rod cone dystrophy
-Polydactyly
-Obesity
-Genital anomalies
- Renal anomalies
- Learning diabilities
Secondary Criteria:
- Speech delay
- Developmental
delay
- Diabetes mellitus
- Dental anomalies
-Congenital Heart
disease
-Brachydactyly
-Ataxia/Poor
coordination
- Anosmia/Hyposmia
Forsythe and Beales.Eur J Hum genet.2013;21:8-13
Alstrm syndrome: ALMS1 deficiency
Mutation in ALMS1 gene.
ALMS1 plays role in LEPR
signaling and POMC neuron
survival
<1:1,000,000 (~900 cases)
Alstrm syndrome: Clinical Characteristics
v
Albright Hereditary Osteodystrophy
Inactivating mutation in GNAS
Inherited from the mother, can
be associated with resistance to
certain hormones, in particular
the PTH. This is
Pseudohypoparathyroidism type
1A.
When inherited from father , no
hormone resistance but an AHO
phenotype .
Albright Hereditary Osteodystrophy
phenotype
Developmental delay
Short stature
Round facies
Short fourth and fifth
metacarpals
Brachydactyly
Hypocalcemia ( in PHP1
A)
Fragile X Syndrome
Obesity in upto 60% of
cases
1/2,500 births X-linked
FMR1 gene (Xq27.3)
Intellectual disability,
hyperkinetic behavior,
macroorchidism, large ears,
prominent jaw
Benefits of Identifying Genetic Cause
Families relieved to know cause, feel less blame
Anticipatory guidance and screening
Social support groups provide community
Management of hyperphagia as a physiologic medical condition
Distinct approach from traditional nutritional counseling for obesity
Food dosed and timed similar to prescription medications
In hypotonic conditions, 20% to 40% lower caloric needs due to decreased lean mass
Growth hormone therapy approved for PWS – increases muscle mass and tone, reduces truncal
obesity, potential cognitive benefits when initiated early
Genetic diagnosis o opportunity for targeted treatment
Styne DM, et al. J Clin Endocrinol Metab. 2017;102(3):709-57; Rubin DA, et al. Food Nutr Res. 2015;59:29427;
Goldstone AP, et al. .J Clin Endocrinol Metab. 2008;93(11):4183-97
Leptin replacement for leptin deficiency
Melanocortin agonist (setmelanotide) under investigation for
LEPR, POMC, PCSK1, and CPE mutations
Targeted approaches being studied for other rare and common
variants of leptin pathway genes
Precision Medicine Based on Genetics
Farooqi IS, et al. J Endocrinol. 2014;223(1):T63-70.
Kühnen P, et al. N Engl J Med. 2016;375(3):240-6.
Clement K, et al. Nat Med. 2018;24(5):551-5.